Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-Hodgkin lymphoma

Clinical Cancer Research

Volumn 17, Issue 23, 2011, Pages 7373-7382

  Park, Steven I ^a   Shenoi, Jaideep ^b,c   Frayo, Shani M ^b   Hamlin, Donald K ^d   Lin, Yukang ^b   Wilbur, D Scott ^d   Stayton, Patrick S ^e   Orgun, Nural ^b   Hylarides, Mark ^b   Buchegger, Franz ^f   Kenoyer, Aimee L ^b   Axtman, Amanda ^b   Gopal, Ajay K ^b,c   Green, Damian J ^b,c   Pagel, John M ^b,c   Press, Oliver W ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e University of Washington   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; CD20 ANTIBODY; PENTETATE INDIUM IN 111; STREPTAVIDIN; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE; PRETARGETED RADIOIMMUNOTHERAPY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SAV GENE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELL LINE, TUMOR; LYMPHOMA, NON-HODGKIN; MICE; MICE, NUDE; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; STREPTAVIDIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82555189376     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1204     Document Type: Article

References (41)

1. Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998;25:483-91.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
3. Horning SJ. Treatment approaches to the low-grade lymphomas. Blood 1994;83:881-4.
4. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy- refractory low-grade or transformed low-grade B-cell non- Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28.
5. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al. Yttrium- 90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70.
6. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20: 2453-63.
7. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18: 1316-23.
8. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, et al. High-dose radioimmunotherapy versus conventional highdose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003;102:2351-7.
9. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
10. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934-42.
11. Goodwin DA, Meares CF, Osen M. Biological properties of biotinchelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J Nucl Med 1998;39:1813-8.
12. Rosebrough SF. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. Nucl Med Biol 1993;20:663-8.
13. Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun 1991;12:211-34.
14. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001;19:435-50.
15. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-302.
16. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802-7.
17. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001;98:2535-43.
18. Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, et al. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 2006;108:328-36.
19. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004;104: 227-36.
20. Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, et al. Pretargeted radioimmunotherapy (RIT) with a novel anti- TAG-72 fusion protein. Cancer Biother Radiopharm 2005;20: 379-90.
21. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
22. Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non- Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000;15:15-29.
23. Baker H. Assessment of biotin status: clinical implications. Ann N Y Acad Sci 1985;447:129-32.
24. Shriver BJ, Roman-Shriver C, Allred JB. Depletion and repletion of biotinyl enzymes in liver of biotin-deficient rats: evidence of a biotin storage system. J Nutr 1993;123:1140-9.
25. Stayton PS, Nelson KE, McDevitt TC, Bulmus V, Shimoboji T, Ding Z, et al. Smart and biofunctional streptavidin. Biomol Eng 1999; 16:93-9.
26. Freitag S, Le Trong I, Chilkoti A, Klumb LA, Stayton PS, Stenkamp RE. Structural studies of binding site tryptophan mutants in the highaffinity streptavidin-biotin complex. J Mol Biol 1998;279:211-21.
27. Hamblett KJ, Kegley BB, Hamlin DK, Chyan MK, Hyre DE, Press OW, et al. A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjug Chem 2002;13:588-98.
28. Wilbur DS, Park SI, Chyan MK, Wan F, Hamlin DK, Shenoi J, et al. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants. Bioconjug Chem 2010;21:1225-38.
29. Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, et al. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. Bioconjug Chem 2005; 16:131-8.
30. Wilbur DS, Chyan MK, Pathare PM, Hamlin DK, Frownfelter MB, Kegley BB. Biotin reagents for antibody pretargeting. 4. Selection of biotin conjugates for in vivo application based on their dissociation rate from avidin and streptavidin. Bioconjug Chem 2000;11:569-83.
31. Wilbur DS, Pathare PM, Hamlin DK, Weerawarna SA. Biotin reagents for antibody pretargeting. 2. Synthesis and in vitro evaluation of biotin dimers and trimers for cross-linking of streptavidin. Bioconjug Chem 1997;8:819-32.
32. Wilbur DS, Hamlin DK, Chyan MK, Kegley BB, Pathare PM. Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability. Bioconjug Chem 2001;12:616-23.
33. Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006;66:3884-92.
34. Klumb LA, Chu V, StaytonPS. Energetic roles of hydrogen bonds at the ureido oxygen binding pocket in the streptavidin-biotin complex. Biochemistry 1998;37:7657-63.
35. Schultz J, Lin Y, Sanderson J, Zuo Y, Stone D, Mallett R, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res 2000;60:6663-9.
36. Pressman D. Radiolabeled antibodies. Ann N Y Acad Sci 1957;69: 644-50.
37. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004;103:4429-31.
38. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with lowgrade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-73.
39. Sung C, van Osdol WW, Saga T, Neumann RD, Dedrick RL, Weinstein JN. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res 1994;54:2166-75.
40. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-8.
41. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003;101:2340-8.